Recombinant humanized III-type collagen as well as preparation method and application thereof

By optimizing the expression system and purification technology of E. coli, the problem of immature collagen extraction methods and low content of type III collagen was solved, and recombinant humanized type III collagen with high hydrophilicity and biological activity was obtained for medical use and skin care areas, addressing the issues of immunogenicity and viral infection risk.

CN119019535APending Publication Date: 2024-11-26ZHEJIANG QINGRONG BIOTECHNOLOGY DEV CO LTD +1
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411135897.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing collagen products mainly come from animal sources. The immature extraction methods lead to damage to the active structure, poor water solubility, and risk of immunogenicity and viral infection. The content of Type III collagen is very small, making it difficult to exert biological activity.

Method used

The E. coli expression system is used to optimize the coding gene of recombinant humanized type III collagen, improve water solubility and expression through His tag and linker sequence, and express it using BL21 (DE3) cells, combined with nickel column affinity chromatography and molecular sieves Purification by desalination and ion exchange chromatography to remove endotoxins, and obtain highly hydrophilic and biologically active recombinant humanized type III collagen.

Benefits of technology

The obtained recombinant humanized type III collagen has high hydrophilicity and biological activity, and has almost no endotoxin activity. It is suitable for medical dressings, skin care products and skin mucosal protective agents, significantly improving the bioefficacy and safety of the product.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004999421100000042
    Figure BDA0004999421100000042
  • Figure BDA0004999421100000051
    Figure BDA0004999421100000051
  • Figure BDA0004999421100000061
    Figure BDA0004999421100000061
Patent Text Reader

Abstract

The invention discloses a recombinant humanized III-type collagen and a preparation method and application thereof.The recombinant humanized III-type collagen is redesigned on the basis of an original gene sequence of the human III-type collagen by selecting a part with high water solubility and high biological activity and optimizing according to escherichia coli codon preference, and the recombinant humanized III-type collagen is obtained through a DNA recombination technology. A Clearcoli BL21 (DE3) expression system is adopted, a biological fermentation technology is utilized to realize large-scale production of the III-type collagen, and the III-type collagen has the characteristics of 100% homologous sequence with the human III-type collagen, strict adherence to a G-X-Y repetitive sequence mode, strong hydrophilicity, high biocompatibility, no endotoxin hidden danger and the like. In addition, proliferation, adhesion, differentiation and wound healing of human fibroblasts can be remarkably promoted, and the method can be widely applied to the fields of skin care products, skin repair dressings, biological materials and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of genetic engineering, and in particular relates to a recombinant humanized type III collagen and a preparation method and application thereof. Background Art

[0002] Collagen is the most abundant protein in the human body, accounting for more than 30% of the total protein. A large number of studies have shown that collagen hydrolysates have significant biological activities, such as antioxidant properties, antihypertensive activity, lipid-lowering activity, and repair properties of damaged skin. Collagen has a dual role in the skin: providing building blocks for the formation of elastin and collagen, acting as a ligand or binding to fibroblast receptors to stimulate the synthesis of hyaluronic acid. Based on the above characteristics, collagen has a wide range of applications in the medical and health fields such as burns, trauma, corneal diseases, health care, beauty, orthopedics, hard tissue repair, wound hemostasis, drug delivery, and sustained-release technology.

[0003] At present, most of the various collagen products used in the market are animal collagen or human-like collagen, which mainly come from the skin of common animals such as cows and fish. Due to the immature extraction methods, the active structure of collagen is often destroyed. The final product mainly exists in the form of short collagen peptides, which are poorly water-soluble and cannot play the role of collagen. There are also problems such as immunogenicity, risk of viral infection, and unclear relationship between biologically active sequences and functions. In addition, animal-extracted collagen is mainly type I collagen, with very little type III.

[0004] With the rapid development of genetic engineering technology, recombinant humanized collagen provides an alternative with more controllable risks. A large number of scholars have used recombinant DNA technology to produce recombinant humanized collagen with no immunogenicity and no virus transmission using different hosts as expression systems. Although the expression systems of mammals and transgenic plants and animals are relatively complete, the cost and technical requirements are high, the yield is low, and they are not suitable for large-scale production; the Escherichia coli expression system has the characteristics of short cycle, low cost, and easy large-scale production, which is suitable for large-scale production of type III collagen. However, the endotoxins produced by wild Escherichia coli can cause fever, shock, and even death when entering the human blood. Therefore, the removal of endotoxins is a very critical issue in the development of biological products. Although a certain amount of endotoxins can be removed by the later allantoin, cerium nitrate method, phase separation method, and affinity chromatography coupling method, a large part of the collagen will also be lost. Furthermore, the recombinant humanized type III collagen or recombinant humanized type III collagen / recombinant humanized type II collagen chimera prepared by wild Escherichia coli lacks functional motifs, and some peptide sequences destroy the characteristic Gly-XY repeating sequence of collagen. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present invention provides a recombinant humanized type III collagen and a preparation method and application thereof.

[0006] In a first aspect, an embodiment of the present invention provides a recombinant humanized type III collagen, the amino acid sequence of the recombinant humanized type III collagen is shown in SEQ NO.1.

[0007] In a second aspect, an embodiment of the present invention provides a gene encoding recombinant humanized type III collagen, characterized in that the nucleotide sequence of the gene encoding is as shown in SEQ NO.3.

[0008] Furthermore, the nucleotide sequence SEQ NO.3 is obtained by optimizing the nucleotide sequence SEQ NO.2 according to the codon preference of Escherichia coli and adding a His tag at the 3' end.

[0009] Furthermore, the nucleotide sequence SEQ NO.2 is obtained by tandemly repeating the linker sequence (GGGATCTGTGAATCTTGC) of SEQ NO.4 having the Gly-XY tripeptide repeat sequence characteristics of the α1 chain collagen domain of human type III collagen.

[0010] In a third aspect, an embodiment of the present invention provides a recombinant vector constructed with the gene encoding the recombinant humanized type III collagen as described in claim 2.

[0011] Furthermore, the recombinant vector is PET28A.

[0012] In a fourth aspect, an embodiment of the present invention provides a recombinant genetically engineered bacterium constructed by the recombinant vector described in claim 5.

[0013] Furthermore, the recombinant genetically engineered bacteria is BL21(DE3).

[0014] In a fifth aspect, an embodiment of the present invention provides a method for preparing recombinant humanized type III collagen, characterized in that the method comprises:

[0015] Synthesize the coding gene of recombinant humanized type III collagen SEQ NO.3;

[0016] Connect the coding gene SEQ NO.3 to the recombinant vector and transfer it into bacteria by electroporation to construct a recombinant genetic engineering bacterium;

[0017] Fermenting and culturing the recombinant genetically engineered bacteria and inducing expression to obtain a fermentation liquid;

[0018] Centrifuging the fermentation broth, collecting the bacteria, resuspending the lysate, breaking it, and collecting the supernatant;

[0019] The supernatant was subjected to nickel column affinity chromatography, molecular sieve desalting treatment and ion exchange chromatography to obtain recombinant humanized type III collagen.

[0020] In a sixth aspect, an embodiment of the present invention provides a use of recombinant humanized type III collagen in the preparation of medical dressings, in the preparation of skin care products and / or in the preparation of skin and mucous membrane protective agents.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] (1) The recombinant humanized type III collagen RCHⅢ prepared by the present invention is composed of two completely identical human type III collagen fragments with high hydrophilicity, which are repeated in tandem through a cysteine ​​linker that can form a disulfide bond, thereby ensuring that it has a certain degree of cross-linking on the basis of consistency with the natural amino acid composition, and has higher biological activity and hydrophilicity.

[0023] (2) The recombinant humanized type III collagen RCHⅢ prepared by the present invention is used The expression was carried out in BL21(DE3) Escherichia coli. BL21(DE3) cells have modified LPS, and compared with wild-type BL21(DE3), the prepared heterologous proteins have almost no endotoxin activity and will not trigger the endotoxin response of human cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the accompanying drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the accompanying drawings in the following description are only some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying creative labor.

[0025] Figure 1 A diagram showing the hydrophilicity analysis results of the recombinant humanized type III collagen RCHⅢ provided in an embodiment of the present invention;

[0026] Figure 2 The SDS-PAGE electrophoresis diagram of the recombinant humanized type III collagen RCHⅢ provided in the embodiment of the present invention;

[0027] Figure 3 The nickel agarose affinity chromatography purification chromatogram and electrophoresis diagram of the recombinant humanized type III collagen RCHⅢ provided in the embodiment of the present invention;

[0028] Figure 4 The chromatogram and electrophoresis diagram of the recombinant humanized type III collagen RCHⅢ provided in the embodiment of the present invention after passing through G25 molecular sieve;

[0029] Figure 5The chromatogram and electrophoresis diagram of the recombinant humanized type III collagen RCHⅢ after ion exchange provided in the embodiment of the present invention;

[0030] Figure 6 A diagram showing the mass spectrometry analysis results of recombinant humanized type III collagen RCHⅢ provided in an embodiment of the present invention;

[0031] Figure 7 The infrared spectrum of the recombinant humanized type III collagen RCHⅢ provided in the embodiment of the present invention;

[0032] Figure 8 A scanning electron micrograph of the recombinant humanized type III collagen RCHⅢ provided in an embodiment of the present invention;

[0033] Fig. 9 Schematic diagram of the cytotoxicity, cell proliferation, cell adhesion, cell spreading, cell migration and cell differentiation of the recombinant humanized type III collagen RCHⅢ provided in the embodiments of the present invention. DETAILED DESCRIPTION

[0034] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0035] It should be noted that, in the absence of conflict, the features in the following embodiments and implementations may be combined with each other.

[0036] The present invention provides a recombinant humanized type III collagen, the amino acid sequence of which is shown in SEQ NO. 1. The nucleotide sequence of the gene encoding the recombinant humanized type III collagen is shown in SEQ NO. 3.

[0037] Example 1: Construction of RCHIII expression strain and induced expression

[0038] 1. Construction of RCHⅢ expression strain

[0039] (1) Based on the Gly-XY tripeptide repeat sequence characteristics of the α1 chain collagen domain of human type III collagen, in order to improve the water solubility of collagen and increase the expression level, hydrophobic amino acids (such as Trp, Tyr, Phe, Leu, Ile, Val, Met, etc.) other than Pro are replaced with hydrophilic amino acids (such as Asp, Asn, Glu, Gln, etc.), forming a new gene sequence with various amino acid contents close to those of natural human collagen and with the Gly-XY characteristic of human type III collagen, as shown in SEQ NO.4;

[0040] (2) The above SEQ NO.4 is repeated in tandem through a disulfide bond linker sequence to form a new human type III collagen, whose nucleotide sequence is as shown in SEQ NO.2;

[0041] (3) Optimizing SEQ NO.2 according to the codon preference of E. coli, the nucleotide sequence after optimization is as SEQ NO.3;

[0042] (4) Artificially synthesizing the above SEQ NO.3, and then directly connecting the sequence to the plasmid PET28A to obtain the PET28A-RCHⅢ recombinant plasmid;

[0043] (5) The plasmid was transferred into BL21(DE3) competent cells were coated on anti-kanamycin plates and cultured at 37°C overnight. Monoclonal colonies were selected as expression strains.

[0044] Table 1: Sequence Listing

[0045]

[0046]

[0047]

[0048] The recombinant humanized collagen of the present invention is a new gene sequence designed and synthesized based on the amino acid sequence of its collagen domain with the purpose of improving the water solubility of collagen and increasing the expression amount, while maintaining the characteristics of collagen. The corresponding protein is composed entirely of Gly-XY tripeptide repeating sequences, and the content of various amino acids is close to that of natural human collagen. Except for Pro, hydrophobic amino acids (such as Trp, Tyr, Phe, Leu, Ile, Val, Met, etc.) are replaced with hydrophilic amino acids (such as Asp, Asn, Glu, Gln, etc.), thereby improving the hydrophilicity of recombinant human collagen. The hydrophilicity analysis results are shown in the attached figure. Figure 1As shown, negative values ​​represent hydrophilicity; positive values ​​represent hydrophobicity, and the lower the hydrophilicity evaluation score is, the better the hydrophilicity is. Figure 1 The minimum value is -2.622 and the maximum value is 0.733, and the test result is hydrophilic. The RCHⅢ has a unique chemical structure and performance that is superior to animal collagen.

[0049] 2. Inducible expression of RCHⅢ

[0050] (1) Activation: Pick a single clone of bacteria and culture it in 1 ml of LB medium containing kanamycin resistance (5 g / L yeast extract, 10 g / L tryptone, 10 g / L NaCl, 50 ug / mL kanamycin) for 6-8 h. Use this medium as a template to perform bacterial liquid PCR. Inoculate the strain with the correct sequencing result into 5 mL of liquid LB medium containing kanamycin resistance and culture it at 37°C for 8-12 hours to serve as the seed liquid.

[0051] (2) Induction: When the OD value reached 0.6-0.8, IPTG was added for induction. The induction was carried out at 20°C overnight and at 37°C for 6 hours. A negative control without the addition of inducer was used.

[0052] (3) Collecting bacteria: Centrifuge at 6000 rpm for 20 min, discard the supernatant, and collect the bacteria;

[0053] (4) Expression detection: Buffer A (PBS, pH 7.4) was added to the collected bacteria for suspension, and the cells were fully dissolved using an ultrasonic disruptor and centrifuged. The precipitate after centrifugation was dissolved using buffer B (8 M Urea, 50 mM Tris-HCl, 300 mM NaCl, pH 8.0). The supernatant and precipitate were treated separately, and samples were prepared for SDS-PAGE and Western Blot detection.

[0054] (5) Large-scale expression: The cultured seed solution was expanded at a 1% inoculation ratio. The culture conditions were 37°C, 200 rpm, until the OD value reached 0.6-0.8, 0.5 mM IPTG was added to the culture solution, cultured overnight at 20°C, and centrifuged at 6000 rpm for 20 min to collect the bacteria.

[0055] The expression detection results of this example are shown in the attached Figure 2 As shown, Figure 2 (A) M: Marker; 1: total protein before induction; 2: 20°C supernatant; 3: 20°C precipitate; 4: 37°C supernatant; 5: 37°C precipitate. Figure 2 (B) M: Marker; 1: 20℃ supernatant. Figure 2The fusion protein in (A) was shown in the figure. It can be seen that the supernatant at 20°C and 37°C contained induced expression protein. In order to further determine whether the target protein was expressed, the TBM colorimetric kit was used for Western blot detection. The results are shown in the attached figure. Figure 2 As shown in (B), the target protein is indeed expressed in the supernatant at 20°C. Since there are fewer protein bands in the supernatant at 20°C, the 20°C condition is selected for large-scale induction expression and used for subsequent purification. The present invention can ensure high expression of recombinant humanized collagen after the preferred codon design of Escherichia coli, and the above-mentioned optimized fermentation conditions can further increase the yield.

[0056] Example 2: RCHIII purification

[0057] 1. Ni column affinity chromatography

[0058] (1) Filler: Ni-TED, 1.3 mL (10 mm chromatography column);

[0059] (2) Buffer: Solution A is 20 mM Tris, 500 mM NaCl, pH 7.4; Solution B is 20 mM Tris, 500 mM NaCl, 500 mM IM, pH 7.4;

[0060] (3) Sample treatment: The supernatant after bacterial cell disruption was filtered with a 0.8 μm filter and 0.2% TritonX-100 and 0.1% PMSF were added;

[0061] (4) Purification process: 15 mL was injected at 0.5 mL / min, solution A was eluted until the baseline was stable, and 2% B, 3% B, 4% B, 8% B, 10% B, 60% B and 100% B were used for elution, and the detection wavelength was 214 nm;

[0062] (5) Detection: The chromatogram and SDS-PAGE electrophoresis results are shown in the attached Figure 3 (A) and Figure 3 (B) in the figure are the elution test results of 2% B solution, 3% B solution, 4% B solution, 8% B solution, 10% B solution, 60% B solution and 100% B solution. The components of B solution are 20mM Tris, 500mM NaCl, 500mM IM, pH 7.4. The target protein can be eluted by 2%-100% B elution, among which the target protein eluted by 8%-60% B is more. In order to further desalt and remove imidazole, it is collected for G25 molecular sieve purification.

[0063] 2.G25 molecular sieve

[0064] (1) Filler: G25, 50 mL (16 mm chromatography column);

[0065] (2) Buffer: Solution C is 20 mM PB, 1 mM EDTA, pH 6.0;

[0066] (3) Purification process: After mixing the 8-60% B part of Ni-TED, 12 mL was injected at 2 mL / min, and the entire C solution was 2 mL / min, running for 3 column volumes, and the detection wavelength was 214 nm;

[0067] (4) Detection: The chromatogram and SDS-PAGE electrophoresis results are shown in the attached Figure 4 (A) and Figure 4 In (B), 1-11 are the results of the test of the 8-60% B solution of Ni-TED after mixing and injecting at 2mL / min through G25 molecular sieve. 1-8 all have obvious target proteins eluted, and in order to further remove the impurities, they are collected for ion exchange chromatography for further purification.

[0068] 3. Ion exchange chromatography

[0069] (1) Filler: HP-SP, 1 mL (6.6 mm chromatography column);

[0070] (2) Buffer: Solution C: 20 mM PB, 1 mM EDTA, pH 6.0; Solution D: 20 mM PB, 1 mM EDTA, 500 mM NaCl, pH 6.0;

[0071] (3) Purification process: After mixing tubes 1-8 of G25, inject at 0.3 mL / min, elute with solution C until the baseline is stable, elute with 0-100% solution D at 1 mL / min for 40 column volumes, and detect at a wavelength of 214 nm;

[0072] (4) Detection: The chromatogram and SDS-PAGE electrophoresis results are shown in the attached Figure 5 (A) and Figure 5 In (B), 1-9 are the test results of the ion exchange column eluate after mixing the samples of tubes 1-8 of G25 molecular sieve. There are no impurities in 1-9, and the target protein with high purity is obtained.

[0073] The RCHⅢ expressed by the present invention has extremely low impurity protein content after purification and high purity, and is suitable for use in the fields of skin care products, biomaterials, etc.

[0074] Example 3: Characterization of RCHIII

[0075] In order to further identify whether the protein obtained above is RCHⅢ, protein identification was performed. Then, infrared spectroscopy and scanning electron microscopy were performed on the obtained RCHⅢ to analyze its characteristics.

[0076] 1. RCHⅢ mass spectrometry identification

[0077] (1) Sample enzymatic hydrolysis: After the target protein sample obtained above was reduced and alkylated, an appropriate amount of trypsin (mass ratio 1:50) was added and enzymatic hydrolyzed at 37°C for 20 hours. After desalting, the sample was freeze-dried and redissolved in 0.1% FA solution and stored at -20°C for later use;

[0078] (2) Mass spectrometry analysis: Liquid A is a 0.1% formic acid aqueous solution, and liquid B is a 0.1% formic acid acetonitrile aqueous solution (acetonitrile is 84%). After the chromatographic column is equilibrated with 95% liquid A, the sample is loaded onto the Trap column by an automatic sampler. After chromatographic separation, the sample is analyzed by mass spectrometry using a mass spectrometer. The detection method is positive ion, the parent ion scanning range is 300–1800 m / z, the primary mass spectrometry resolution is 70,000 at 200 m / z, the AGC (Automatic gain control) target is 1e6, the Maximum IT is 50 ms, and the dynamic exclusion time is 30.0 s. The mass-to-charge ratios of peptides and peptide fragments were collected according to the following method: 20 fragment spectra (MS2 scan) were collected after each full scan (full scan), MS2 Activation Type was HCD, Isolation window was 2 m / z, secondary mass spectrometry resolution was 17,500 at 200 m / z, Normalized Collision Energy was 27 eV, and Underfill was 0.1%;

[0079] (3) Data analysis: The raw files of mass spectrometry tests were searched in the corresponding database using the search engine Proteome Discoverer2.5.

[0080] The results of this part show that the proteins finally identified are Collagen alpha-1(III) chain OS=Homo sapiens OX=9606GN=COL3A1 PE=1SV=4 and other proteins. Figure 6 The mass spectrometry analysis results of the recombinant humanized type III collagen RCHⅢ provided in the embodiment of the present invention are as follows: Figure 6 (A) shows the coverage, Figure 6 (B) shows the peptide score distribution, Figure 6 (C) shows the protein score distribution. Figure 6 As shown in (A), the matching rate of the identified peptides is as high as 92%. Figure 6 The peptide distribution ion score in (B) is more than 2, and the protein distribution in the attached figure (C) shows that there is only one protein family with 1539, which shows that RCHⅢ was successfully induced.

[0081] 2. RCHⅢ Fourier infrared spectroscopy characterization

[0082] (1) Test method: The prepared samples were measured using an IRSpirit Fourier transform infrared spectrometer, with KBr as the background at room temperature. The infrared spectrum signal of the sample was scanned and accumulated 32 times each time, and the test frequency range was 4000cm-1-400cm-1. -1 , resolution 0.5cm -1 OMNIC software was used to convert the data into absorbance / transmittance and automatically smooth the data.

[0083] (2) Analysis method: The data were peak marked using omnic 8.0, and baseline correction and normalization were performed before peak fitting. The GaussAmp function in peakfit 4.12 was used to fit the processed data, and the spectrum was drawn using Origin 2017 software.

[0084] The test results of this embodiment are shown in the attached Figure 7 , RCHⅢ at 3442cm -1 The absorption peak at 3123 cm is located in the protein amide A band, which is a mixed absorption peak of OH and NH stretching vibration. -1 The shoulder peak (amide B band) at 1655cm originates from the NH stretching vibration and also includes the unsaturated aliphatic / aromatic =CH stretching vibration mode on the amino acid side chain. -1 The absorption peak near (amide I band) is the C=O stretching vibration mode in the amide group (-NH-CO-) of the polypeptide, indicating that the polypeptide has a secondary structure in the protein substance. -1 The absorption peak at 1263 cm (amide II band) is mainly related to the NH bending and CN stretching vibration modes in the primary and secondary amine groups (-NH-CO-) of polypeptides. -1 The absorption peak near 1158cm (amide III band) originates from the CN stretching vibration mode of the amide group. -1 and 1069cm -1 The absorption peak nearby is related to the CO stretching vibration mode, which is the characteristic peak of type III collagen. From the above characteristics, it can be seen that the samples all have obvious absorption peaks in the amide band, which is consistent with the characteristics of type III collagen.

[0085] 3. Scanning electron microscopy characterization of RCHⅢ

[0086] (1) The above RCHⅢ is treated by a freeze dryer to obtain collagen sponge;

[0087] (2) The collagen sponge sample obtained above was directly glued to the sample stage with conductive glue and then sprayed with gold for 30 seconds. The sample was photographed using a Zeiss sigma300 scanning electron microscope (SEM), with an energy spectrum model of OXFORD X-max 50 and an operating voltage of 3 kV.

[0088] The test results of this embodiment are shown in the attached Figure 8 , RCHⅢ consists of tightly connected filaments ( Figure 8 (A) left) or intertwined sheets ( Figure 8 (A) right) is composed of a porous structure ( Figure 8 (B) in the figure indicates that the RCHⅢ has certain adhesion properties and has a certain adhesion effect on cells, and has certain applications in the field of biomaterials.

[0089] Example 4: RCHⅢ impurities, contaminants and safety testing

[0090] To further evaluate the safety of RCHⅢ obtained by the present invention, endotoxin, residual DNA and E. coli protein residues of RCHⅢ were detected by using horseshoe crab reagent, PicoGreen fluorescence kit and E. coli host residual protein (E. coli-P) enzyme-linked immunosorbent assay kit. The detection method was carried out with reference to the steps of the kit, and the detection results are shown in Table 1.

[0091] Table 1

[0092]

[0093] The test results of this example show that the safety of RCHⅢ meets the quality test standards for medical-grade recombinant collagen and can be used in the fields of skin care and biomaterials.

[0094] Example 5: Evaluation of biological function of RCHⅢ

[0095] 1. Cytotoxicity

[0096] The cytotoxicity of the samples was evaluated by Cell Counting Kit-8 (CCK-8), and the samples included RCHⅢ obtained in the present invention, commercial RCHⅢ, and bovine Achilles tendon collagen standard (positive control). The specific operation is as follows:

[0097] (1) A control group (containing culture medium, CCK-8, but no sample to be tested), a blank group (containing no cells and culture medium, but containing CCK-8), and an experimental group (containing culture medium, CCK-8, and sample to be tested) were set up respectively.

[0098] There are at least 3 parallel groups;

[0099] (2) Take 100 μL of HFF-1 cell suspension (concentration 3x10 4 -5x10 4 / mL) were inoculated into a 96-well cell culture plate, the edges were filled with PBS, and incubated at 37°C, 5% CO2;

[0100] (3) After 24 h of culture, the culture medium was discarded, 100 μL of the sample to be tested (dissolved in DMEM medium) was added to the experimental group, and an equal volume of DMEM medium was added to the control group, and the cells were incubated at 37°C with 5% CO2;

[0101] (4) After 24 h of culture, discard the old solution, add 100 μL of 10% CCK-8 cell culture solution to each well, and incubate in a cell culture incubator for 2 h;

[0102] (5) Measure the absorbance at 450 nm using an enzyme-labeled instrument. Each experiment was performed in parallel three times.

[0103] (6) Cell survival rate = (experimental group - blank group) / (control group - blank group) × 100%.

[0104] 2. Cell Proliferation

[0105] The CCK-8 method was used to detect the ability of the sample to promote HFF-1 cell proliferation, and the sample included RCHⅢ obtained by the present invention, commercial RCHⅢ and bovine Achilles tendon collagen standard (positive control). The specific operation was as follows:

[0106] (1) Take HFF-1 cell suspension and add 5×10 cells per well. 3 The cells were seeded at a density of 10 cells / well in a 96-well plate and cultured at 37°C, 5% CO2 for 24 h;

[0107] (2) Discard the culture medium, add 100 μL of the sample to be tested at different concentrations, replicate 4-6 times for each concentration, culture at 37°C, 5% CO2 for an appropriate period of time (e.g., 1st, 4th, 7th, 11th day), and take photos;

[0108] (3) The culture medium was replaced every 2 days. When the culture medium reached the experimental date, the culture medium was replaced with 100 μL of serum-free DMEM medium containing 10% (v / v) CCK-8 reagent and the culture was continued at 37°C and 5% CO2 for 2 h.

[0109] (4) The absorbance at 450 nm was measured using an ELISA reader and analyzed using Origin.

[0110] 3. Cell Adhesion

[0111] The ability of the samples to promote HFF-1 cell adhesion was detected by DNA quantitative determination method, and the samples included RCHⅢ obtained by the present invention, commercial RCHⅢ and bovine Achilles tendon collagen standard (positive control).

[0112] The specific operations are as follows:

[0113] (1) 0.5 mg / mL recombinant collagen and heat-denatured BSA were added to untreated 96-well plates and placed at 4°C for 24 h.

[0114] (2) Heat-denatured BSA was used as a negative control, and bovine Achilles tendon collagen was used as a positive control.

[0115] (3) Carefully aspirate the supernatant and add 100 μL of HFF-1 cell suspension (5×10 5 cell / mL) and incubated at 37°C, 5% CO2 for 6 hours. The culture medium was discarded and the cells were washed 3 times with PBS.

[0116] (4) The spreading of HFF-1 cells on the recombinant collagen surface was observed under bright field conditions using a living cell workstation and photographed.

[0117] (5) Add 100 μL of Hoechst 33258 at a final concentration of 5 μg / mL. Lyse the cells by three freeze-thaw cycles, and incubate the mixture in the dark for 1 h.

[0118] (6) The emission value at 465 nm was measured using a multifunctional microplate reader at an excitation wavelength of 360 nm. Each sample was measured in parallel three times, and the data were expressed as mean ± standard deviation, and analyzed using GraphPad Prism 8.

[0119] 4. Cell Spreading

[0120] The spreading of HFF-1 cells on the surface of RCHⅢ, the samples including RCHⅢ obtained by the present invention, commercial RCHⅢ and bovine Achilles tendon collagen standard (positive control) was observed under a microscope in bright field state. The specific operation is as follows:

[0121] (1) 300 μL of 0.5 mg / mL recombinant collagen and heat-denatured BSA were added to non-tissue treated 24-well plates and placed at 4°C for 24 hours.

[0122] (2) Heat-denatured BSA was used as a negative control, and bovine Achilles tendon collagen was used as a positive control.

[0123] (3) Carefully aspirate the supernatant and then add 300 μL of HFF-1 cell suspension (5×10 5 cell / mL) and incubated at 37°C for 24 hours.

[0124] (4) Use a living cell workstation to collect cell images under bright field conditions.

[0125] 5. Cell Migration

[0126] The ability of RCHⅢ, commercial RCHⅢ and bovine Achilles tendon collagen (positive control) to promote HFF-1 cell migration was detected by cell scratch method. The specific operation steps are as follows:

[0127] (1) Use a marker to draw three horizontal lines on the bottom of a 6-well plate, with each line spaced 0.5-1 cm apart.

[0128] (2) Add 6×105 cells to each well and culture for 24 h.

[0129] (3) Use a 10 μL pipette tip to draw a line vertically along the horizontal line of the ruler perpendicular to the bottom to form a cell scratch. Wash three times with PBS to remove the detached cells.

[0130] (4) Using DMEM culture medium as the control group, 2 ml of the recombinant protein solution was added to each of the 6-well plates and cultured at 37°C and 5% CO2. The plates were taken out at 0 h, 24 h, and 48 h, and the scratched areas were photographed under a living cell workstation.

[0131] 6. Cell Differentiation

[0132] RT-PCR was used to measure the expression of cell differentiation markers α-smooth muscle actin (α-SMA) and vimentin to detect the ability of RCHⅢ, commercial RCHⅢ and bovine Achilles tendon collagen (positive control) to promote HFF-1 cell differentiation. The specific steps are as follows:

[0133] (1) HFF-1 cells were cultured at 5×10 6 cells / mL were inoculated into wells containing RCHⅢ and cultured for 7 days;

[0134] (2) Wash the cell complex with PBS, extract RNA according to the RNA extraction reagent operating procedures, and measure the RNA concentration using a NanoDrop micrometer;

[0135] (3) Reverse transcribe RNA into cDNA according to the instructions of the RT-PCR kit;

[0136] (4) Use TB Green qPCR to analyze the relative expression of genes on a qRT-PCR instrument, using 2- △△Ct The expression level of each target gene relative to the internal reference gene GAPDH was calculated.

[0137] Table 2: Gene primer information used for qRT-PCR

[0138]

[0139] The test results of this embodiment are shown in the attached Fig. 9 The RCHⅢ obtained in the present invention is non-toxic to cells within the concentration range tested, just like commercial RCHⅢ and bovine Achilles tendon collagen (see Appendix Fig. 9 RCHⅢ can promote the proliferation of HFF-1 cells, and its effect is not significantly different from that of bovine Achilles tendon collagen standard and commercial RCHⅢ (Appendix Fig. 9 Microscopic observation of cell adhesion experiment (see (B)). Fig. 9 (C)) and Hoechst 33258 fluorescence detection (Attached Fig. 9 The results in (D) indicate that RCHⅢ has the effect of promoting HFF-1 cell adhesion. Further cell spreading experiment results show that RCHⅢ can significantly promote HFF-1 cell spreading (see Appendix Fig. 9 The results of cell migration showed that RCHⅢ could significantly promote the migration of HFF-1 cells and had similar effects to those of standard products and commercial collagen (see Appendix Fig. 9 The cell differentiation ability of collagen was evaluated by detecting the expression of α-SMA and Vimentin in HFF-1 cells. The results showed that RCHⅢ had a significant ability to promote HFF-1 cell differentiation, and the effect was comparable to that of standard and commercial collagen (see Appendix Fig. 9 (G) in the figure.

[0140] The results of the above embodiments show that the RCHⅢ of the present invention has no endotoxin risk, stable quality, high hydrophilicity, can significantly promote cell proliferation, adhesion, migration and differentiation, and can be applied to skin care, biomaterials and medical fields.

Claims

1. A recombinant humanized type III collagen, characterized in that: The amino acid sequence of the recombinant humanized type III collagen is shown in SEQ NO.

1.

2. A gene encoding recombinant humanized type III collagen as claimed in claim 1, characterized in that: The nucleotide sequence of the coding gene is shown in SEQ NO.

3.

3. The gene encoding recombinant humanized type III collagen according to claim 2, characterized in that: The nucleotide sequence SEQ NO.3 is obtained by optimizing the nucleotide sequence SEQ NO.2 according to the codon preference of Escherichia coli and adding a His tag at the 3' end.

4. The gene encoding recombinant humanized type III collagen according to claim 3, characterized in that: The nucleotide sequence SEQ NO.2 is obtained by tandemly repeating SEQ NO.4 having the Gly-XY tripeptide repeat sequence characteristics of the α1 chain collagen domain of human type III collagen through a linker sequence (GGGATCTGTGAATCTTGC).

5. A recombinant vector constructed with the gene encoding the recombinant humanized type III collagen as claimed in claim 2.

6. The recombinant vector constructed by the gene encoding recombinant humanized type III collagen according to claim 5, characterized in that: The recombinant vector is PET28A.

7. A recombinant genetically engineered bacterium constructed with the recombinant vector according to claim 5.

8. The recombinant genetically engineered bacteria constructed by the recombinant vector according to claim 7, characterized in that: The recombinant genetically engineered bacteria is BL21(DE3).

9. A method for preparing recombinant humanized type III collagen, characterized in that: The method comprises: Synthesize the coding gene of recombinant humanized type III collagen SEQ NO.3; Connect the coding gene SEQ NO.3 to the recombinant vector and transfer it into bacteria by electroporation to construct a recombinant genetic engineering bacterium; Fermenting and culturing the recombinant genetically engineered bacteria and inducing expression to obtain a fermentation liquid; Centrifuging the fermentation broth, collecting the bacteria, resuspending the lysate, breaking it, and collecting the supernatant; The supernatant was subjected to nickel column affinity chromatography, molecular sieve desalting treatment and ion exchange chromatography to obtain recombinant humanized type III collagen.

10. Use of recombinant humanized type III collagen in the preparation of medical dressings, in the preparation of skin care products and / or in the preparation of skin and mucous membrane protective agents.

Citation Information

Cited By

  • Preparation method and application of humanized III-type collagen

    CN119708208A